These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

458 related articles for article (PubMed ID: 32246101)

  • 1. Controversies of renin-angiotensin system inhibition during the COVID-19 pandemic.
    South AM; Tomlinson L; Edmonston D; Hiremath S; Sparks MA
    Nat Rev Nephrol; 2020 Jun; 16(6):305-307. PubMed ID: 32246101
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Can beta-adrenergic blockers be used in the treatment of COVID-19?
    Vasanthakumar N
    Med Hypotheses; 2020 Sep; 142():109809. PubMed ID: 32388480
    [No Abstract]   [Full Text] [Related]  

  • 3. Sound Science before Quick Judgement Regarding RAS Blockade in COVID-19.
    Sparks MA; South A; Welling P; Luther JM; Cohen J; Byrd JB; Burrell LM; Batlle D; Tomlinson L; Bhalla V; Rheault MN; Soler MJ; Swaminathan S; Hiremath S
    Clin J Am Soc Nephrol; 2020 May; 15(5):714-716. PubMed ID: 32220930
    [No Abstract]   [Full Text] [Related]  

  • 4. Drugs and the renin-angiotensin system in covid-19.
    Aronson JK; Ferner RE
    BMJ; 2020 Apr; 369():m1313. PubMed ID: 32241880
    [No Abstract]   [Full Text] [Related]  

  • 5. The mechanistic overview of SARS-CoV-2 using angiotensin-converting enzyme 2 to enter the cell for replication: possible treatment options related to the renin-angiotensin system.
    Offringa A; Montijn R; Singh S; Paul M; Pinto YM; Pinto-Sietsma SJ
    Eur Heart J Cardiovasc Pharmacother; 2020 Sep; 6(5):317-325. PubMed ID: 32464637
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association of ACE2 receptor and ACEIs/ARBs with disease severity in COVID-19.
    Sinha S; Sehgal A; Sehgal R
    Drug Discov Ther; 2020; 14(4):161-170. PubMed ID: 32908071
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Renin-Angiotensin-System (RAS) and COVID-19 - On The Prescription of RAS Blockers].
    Kreutz R; Abd El-Hady Algharably E; Ganten D; Messerli F
    Pneumologie; 2020 Sep; 74(9):611-614. PubMed ID: 32916743
    [No Abstract]   [Full Text] [Related]  

  • 8. COVID-19 and renin-angiotensin system inhibition: role of angiotensin converting enzyme 2 (ACE2) - Is there any scientific evidence for controversy?
    Aleksova A; Ferro F; Gagno G; Cappelletto C; Santon D; Rossi M; Ippolito G; Zumla A; Beltrami AP; Sinagra G
    J Intern Med; 2020 Oct; 288(4):410-421. PubMed ID: 32459372
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Spironolactone may provide protection from SARS-CoV-2: Targeting androgens, angiotensin converting enzyme 2 (ACE2), and renin-angiotensin-aldosterone system (RAAS).
    Cadegiani FA; Goren A; Wambier CG
    Med Hypotheses; 2020 Oct; 143():110112. PubMed ID: 32721806
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Would ACEIs/ARBs be beneficial for COVID-19 patients without hypertension?
    Huang Y; Xie C; Chen X; Hong Q; Huang H
    Pharmacol Res; 2020 Sep; 159():104959. PubMed ID: 32505834
    [No Abstract]   [Full Text] [Related]  

  • 11. Coronavirus disease 2019 (COVID-19) and the renin-angiotensin system: A closer look at angiotensin-converting enzyme 2 (ACE2).
    Zemlin AE; Wiese OJ
    Ann Clin Biochem; 2020 Sep; 57(5):339-350. PubMed ID: 32369402
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The renin-angiotensin-aldosterone system: Role in pathogenesis and potential therapeutic target in COVID-19.
    Braga CL; Silva-Aguiar RP; Battaglini D; Peruchetti DB; Robba C; Pelosi P; Rocco PRM; Caruso-Neves C; Silva PL
    Pharmacol Res Perspect; 2020 Aug; 8(4):e00623. PubMed ID: 32658389
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Use of Renin-Angiotensin System Blockers During the COVID-19 Pandemic: Early Guidance and Evolving Evidence.
    Turgeon RD; Zieroth S; Bewick D; Chow CM; Clarke B; Cowan S; Fordyce CB; Fournier A; Gin K; Gupta A; Hardiman S; Jackson S; Lau B; Leong-Poi H; Mansour S; Marelli A; Quraishi AR; Roifman I; Ruel M; Sapp J; Singh G; Small G; Virani S; Wood DA; Krahn A
    Can J Cardiol; 2020 Aug; 36(8):1180-1182. PubMed ID: 32502522
    [No Abstract]   [Full Text] [Related]  

  • 14. Renin-angiotensin system and SARS-CoV-2 interaction: underlying mechanisms and potential clinical implications.
    Hrenak J; Zorad S; Simko F
    Gen Physiol Biophys; 2020 May; 39(3):203-204. PubMed ID: 32525813
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Direct SARS-CoV-2 infection of the heart potentiates the cardiovascular sequelae of COVID-19.
    Bose RJC; McCarthy JR
    Drug Discov Today; 2020 Sep; 25(9):1559-1560. PubMed ID: 32592868
    [No Abstract]   [Full Text] [Related]  

  • 16. Recombinant human ACE2: potential therapeutics of SARS-CoV-2 infection and its complication.
    Pang X; Cui Y; Zhu Y
    Acta Pharmacol Sin; 2020 Sep; 41(9):1255-1257. PubMed ID: 32581256
    [No Abstract]   [Full Text] [Related]  

  • 17. COVID-19 and relative angiotensin-converting enzyme 2 deficiency: role in disease severity and therapeutic response.
    Ryan PM; Caplice N
    Open Heart; 2020 Jun; 7(1):. PubMed ID: 32532804
    [No Abstract]   [Full Text] [Related]  

  • 18. What would Sérgio Ferreira say to your physician in this war against COVID-19: How about kallikrein/kinin system?
    Nicolau LAD; Magalhães PJC; Vale ML
    Med Hypotheses; 2020 Oct; 143():109886. PubMed ID: 32504925
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Drugs acting on renin angiotensin system and use in ill patients with COVID-19.
    Alexandre J; Cracowski JL; Richard V; Bouhanick B;
    Therapie; 2020; 75(4):319-325. PubMed ID: 32553503
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Vitamin D Supplementation: A Potential Approach for Coronavirus/COVID-19 Therapeutics?
    Arboleda JF; Urcuqui-Inchima S
    Front Immunol; 2020; 11():1523. PubMed ID: 32655583
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 23.